This biotechnology discovers essential proteins using a heavy chain, single polypeptide mini-antibody platform provided by Madrid, Spain-based Bacmine SL, and its Innovators, Pablo Pomposiello, PhD, and Victor de Lorenzo, PhD. Open Therapeutics will freely provide the global community with the essential proteins that pathogens and cancer cells require to survive. By characterizing essential proteins, the research community can collaboratively develop antibiotics to target the pathogens. In addition to the first release of E. coli essential proteins, Drs. Pomposiello and Su are working toward discovering and freely providing additional essential proteins to scientists around the world.
